Humacyte (NASDAQ:HUMA) & Relay Therapeutics (NASDAQ:RLAY) Financial Analysis
Humacyte (NASDAQ:HUMA) & Relay Therapeutics (NASDAQ:RLAY) Financial Analysis
Humacyte (NASDAQ:HUMA – Get Rating) and Relay Therapeutics (NASDAQ:RLAY – Get Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.
納斯達克(納斯達克：HUMA-GET評級)和接力治療(納斯達克：RLAY-GET評級)都是醫療公司，但哪項業務更優越？我們將根據這兩家公司的估值、風險、分析師建議、收益、股息、盈利能力和機構持股的強弱對它們進行比較。
Profitability
盈利能力
This table compares Humacyte and Relay Therapeutics' net margins, return on equity and return on assets.
下表比較了Humacyte和Relay治療公司的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Humacyte | 1,971.30% | -74.59% | -35.49% |
| Relay Therapeutics | -17,136.40% | -21.42% | -18.77% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| Humacyte | 1,971.30% | -74.59% | -35.49% |
| 接力治療學 | -17,136.40% | -21.42% | -18.77% |
Analyst Recommendations
分析師建議
This is a breakdown of recent ratings for Humacyte and Relay Therapeutics, as provided by MarketBeat.
這是由MarketBeat提供的Humacyte和Relay治療公司最近的評級細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Humacyte | 1 | 0 | 1 | 0 | 2.00 |
| Relay Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| Humacyte | 1 | 0 | 1 | 0 | 2.00 |
| 接力治療學 | 1 | 1 | 5 | 0 | 2.57 |
Insider & Institutional Ownership
內部人與機構所有權
13.1% of Humacyte shares are owned by institutional investors. 25.0% of Humacyte shares are owned by company insiders. Comparatively, 4.4% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Humacyte 13.1%的股份由機構投資者持有。Humacyte 25.0%的股份由公司內部人士持有。相比之下，Relay Treateutics 4.4%的股份由公司內部人士持有。強大的機構持股表明，大型基金管理公司、對衝基金和捐贈基金相信，一家公司有望實現長期增長。
Risk and Volatility
風險和波動性
Humacyte has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.
Humacyte的貝塔係數為1.14，這意味着其股價的波動性比標準普爾500指數高14%。相比之下，Relay Treateutics的貝塔係數為1.01，這意味着其股價的波動性比標準普爾500指數高1%。
Earnings & Valuation
收益與估值
This table compares Humacyte and Relay Therapeutics' gross revenue, earnings per share and valuation.
下表比較了Humacyte和Relay治療公司的毛收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Humacyte | $1.26 million | 203.78 | -$26.48 million | $0.32 | 7.78 |
| Relay Therapeutics | $3.03 million | 805.97 | -$363.87 million | ($2.66) | -7.59 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| Humacyte | 126萬美元 | 203.78 | -2,648萬美元 | $0.32 | 7.78 |
| 接力治療學 | 303萬美元 | 805.97 | -3.6387億美元 | ($2.66) | -7.59 |
Humacyte has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.
Humacyte的收益比Relay治療公司高，但收入比Relay治療公司低。Relay治療公司的市盈率低於Humacyte，這表明它目前是兩隻股票中更負擔得起的一隻。
Summary
摘要
Humacyte beats Relay Therapeutics on 8 of the 14 factors compared between the two stocks.
Humacyte在兩隻股票比較的14個因素中有8個擊敗了Relay Treateutics。
About Humacyte
關於Humacyte
(Get Rating)
(獲取評級)
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Humacyte，Inc.致力於開發和製造現成的、可植入的和生物工程的人體組織，用於治療多個治療領域中各種解剖位置的疾病和狀況。該公司利用其專有的科學技術平臺來設計和製造人類脱細胞血管(HAVS)。它的研究用HAVs可以很容易地移植到任何患者體內，而不會引起異物反應或導致免疫排斥反應。該公司正在開發一系列HAVs，目標是血管修復、重建和替代市場，包括血管創傷；用於血液透析的動靜脈通路；外周動脈疾病；以及冠狀動脈旁路移植，以及開發用於兒科心臟手術和細胞治療提供的HAVs，包括治療1型糖尿病的胰島細胞移植。該公司成立於2004年，總部設在北卡羅來納州的達勒姆。
About Relay Therapeutics
關於接力療法
(Get Rating)
(獲取評級)
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
接力治療公司是一家臨牀階段的精準藥物公司。它致力於改變藥物發現過程，最初的重點是在有針對性的腫瘤學和遺傳病適應症中加強小分子治療發現。該公司的主要候選產品包括RLY-4008，這是一種口服成纖維細胞生長因子受體2(FGFR2)小分子抑制劑，正在對晚期或轉移性FGFR2改變的實體腫瘤患者進行首次人類臨牀試驗；RLY-2608，一種針對磷酸肌醇3激酶α的領先突變體-PI3KA抑制劑計劃；以及RLY-1971，一種口服蛋白酪氨酸磷酸酶同源區域2區域含磷酸酶-2的口服小分子抑制劑，正處於對晚期實體腫瘤患者的第一階段試驗。它與D.E.Shaw Research，LLC簽訂了合作和許可協議，通過使用D.E.Shaw Research專注於蛋白質運動分析的計算建模能力來研究某些生物靶標，以開發和商業化針對這些靶標的化合物和產品；以及Genentech，Inc.用於RLY-1971的開發和商業化。該公司前身為Alstery，Inc.，並於2015年12月更名為Relay Treateutics，Inc.。Relay治療公司成立於2015年，總部設在馬薩諸塞州劍橋市。
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
接受Humacyte Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Humacyte和相關公司的最新新聞和分析師評級的每日簡要摘要。